What diseases is filgotinib mainly used to treat?

Filgotinib is a selective JAK1 inhibitor that mainly targets chronic inflammatory diseases caused by immune system disorders. Therefore, it is widely used in the treatment of rheumatoid arthritis (RA) and ulcerative colitis (UC) in many countries around the world. Its mechanism of action is based on inhibiting the JAK-STAT signaling pathway, thereby blocking the signaling of multiple inflammatory cytokines, weakening the immune-mediated inflammatory response, and achieving the purpose of improving symptoms and delaying disease progression.

In rheumatoid arthritis, filgotinib is regarded as a new oral small molecule selective immunomodulatory drug. Its advantage is that it can intervene in symptoms such as joint inflammation, joint swelling and pain, morning stiffness and limited activity in the active phase. In overseas practice, filgotinib is often used in patients who have an inadequate response to traditional DMARDs or are intolerant to other JAK inhibitors. Because its highly selective inhibition of JAK1 may theoretically reduce the impact on other JAK family-related side effects, it has become one of the alternative drugs considered by many rheumatologists.

Figotinib is also used in the treatment of ulcerative colitis, another typical chronic inflammatory disease that causes abdominal pain, diarrhea, bloody mucus stools and intestinal ulcers due to continued activation of the intestinal mucosal immune system. When traditional treatments such as aminosalicylic acid, glucocorticoids, and biological agents are difficult to control the disease, small molecule JAK inhibitors provide patients with a new solution. Figotinib reduces intestinal mucosal inflammation by inhibiting a variety of pro-inflammatory signals, helps promote intestinal mucosal repair, and improves patients' quality of life.

It is worth mentioning that because filgotinib has a clear target and is an oral treatment, patients do not need to frequently go to the hospital for drug infusion, thus improving the convenience and compliance of treatment. This is particularly important for patients with long-term chronic diseases, because continued medication is an important condition for maintaining a stable condition.

Reference materials:https://go.drugbank.com/drugs/DB14845